2.16

24.86% 0.43

Pre-market: 1.97 -0.19 -8.80%

Bioxcel Therapeutics Inc (BTAI)

Overview News Price History Option Chain Financials Why BTAI Down? Discussions Forecast

Bioxcel Therapeutics Inc stock is traded at $2.16, with a volume of 102.36M. It is up +24.86% in the last 24 hours and up +562.58% over the past month. BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

Previous Close:

$1.73

Open:

$1.95

24h Volume:

102.36M

Relative Volume:

32.07

Market Cap:

$6.70M

Revenue:

$1.38M

Net Income/Loss:

$-179.05M

P/E Ratio:

-0.3518

EPS:

-6.14

Net Cash Flow:

$-155.03M

1W Performance:

+1.41%

1M Performance:

+562.58%

6M Performance:

+251.22%

1Y Performance:

-32.08%

1-Day Range:

$1.82

$2.82

1-Week Range:

$1.72

$2.82

52-Week Range:

$0.16

$3.30

Bioxcel Therapeutics Inc Stock (BTAI) Company Profile

Name

Bioxcel Therapeutics Inc

Sector

Healthcare (1169)

Industry

Biotechnology (679)

Phone

203-643-8060

Address

555 LONG WHARF DRIVE, NEW HAVEN, CT

Employee

Twitter

@bioxcel_tx

Next Earnings Date

2024-11-12

Latest SEC Filings

BTAI's Discussions on Twitter

Compare BTAI with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BTAI Bioxcel Therapeutics Inc	2.16	6.70M	1.38M	-179.05M	-155.03M	-6.14
VRTX Vertex Pharmaceuticals Inc	479.79	123.21B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	698.74	76.39B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	624.67	37.96B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	246.75	31.94B	2.25B	-278.16M	-42.59M	-2.17
ONC Beone Medicines Ltd Adr	271.80	29.00B	3.32B	-860.46M	-1.04B	-8.32

Bioxcel Therapeutics Inc Stock (BTAI) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-21-24	Downgrade	UBS	Buy → Neutral
Aug-15-23	Downgrade	Mizuho	Buy → Neutral
Jul-17-23	Downgrade	Guggenheim	Buy → Neutral
Mar-10-23	Downgrade	Jefferies	Buy → Hold
Dec-01-22	Upgrade	Goldman	Sell → Neutral
Jul-07-22	Initiated	Mizuho	Buy
Apr-06-22	Reiterated	BofA Securities	Buy
Nov-15-21	Downgrade	Goldman	Neutral → Sell
Apr-09-21	Initiated	Berenberg	Buy
Feb-01-21	Initiated	UBS	Buy
Oct-30-20	Initiated	Goldman	Buy
Sep-02-20	Initiated	Jefferies	Buy
Aug-17-20	Reiterated	H.C. Wainwright	Buy
Jul-08-20	Reiterated	H.C. Wainwright	Buy
Jun-04-20	Initiated	Guggenheim	Buy
Apr-01-20	Initiated	BofA/Merrill	Buy
Feb-26-20	Reiterated	H.C. Wainwright	Buy
Jan-08-20	Reiterated	H.C. Wainwright	Buy
Nov-12-19	Initiated	SunTrust	Buy

View All

Bioxcel Therapeutics Inc Stock (BTAI) Latest News

Mar 01, 2025

Top Penny Stocks To Watch NowFebruary 28th - MarketBeat

Mar 01, 2025

Feb 28, 2025

Sector Update: Health Care Stocks Rise in Late Afternoon Trading -February 28, 2025 at 03:54 pm EST - Marketscreener.com

Feb 28, 2025

Sector Update: Health Care -February 28, 2025 at 03:33 pm EST - Marketscreener.com

Feb 28, 2025

BioXcel Therapeutics Inc’s Bumpy Road: Analyzing the 52-Week Range and Future Prospects - The InvestChronicle

Feb 28, 2025

BioXcel Therapeutics regains compliance with Nasdaq - MSN

Feb 28, 2025

New Haven-based BioXcel avoids delisting from Nasdaq stock exchange - Hartford Business Journal

Feb 28, 2025

BioXcel Therapeutics regains Nasdaq compliance By Investing.com - Investing.com Canada

Feb 28, 2025

Pre-market Movers: BTAI, VRPX, DCGO, NBY... - RTTNews

Feb 28, 2025

BioXcel Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement - Nasdaq

Feb 28, 2025

BioXcel Therapeutics regains Nasdaq compliance - Investing.com

Feb 28, 2025

BioXcel Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule - GlobeNewswire

Feb 28, 2025

How BioXcel Therapeutics Escaped Nasdaq's Delisting Threat After Months Below $1 - StockTitan

Feb 28, 2025

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Shareholders of BioXcel Therapeutics, Inc.(BTAI) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire

Feb 28, 2025

Feb 26, 2025

BTAI stock touches 52-week low at $2.53 amid sharp annual decline - MSN

Feb 26, 2025

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Shareholders of BioXcel Therapeutics, Inc. (BTAI) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire

Feb 26, 2025

Feb 21, 2025

BTAI stock plunges to 52-week low of $2.16 amid market challenges - Investing.com Nigeria

Feb 21, 2025

BTAI stock plunges to 52-week low of $2.16 amid market challenges By Investing.com - Investing.com South Africa

Feb 21, 2025

SHAREHOLDER ALERT: Potential Recovery for BioXcel Therapeutics, Inc. (BTAI) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire

Feb 21, 2025

Feb 20, 2025

A significant driver of top-line growth: BioXcel Therapeutics Inc (BTAI) - SETE News

Feb 10, 2025

You Should Look At The Stock Forecast For BioXcel Therapeutics Inc (NASDAQ: BTAI). - Marketing Sentinel

Feb 10, 2025